Innovating at the Forefront of mRNA LNP Therapies

February 10, 2022 PAO-02-22-R250-08

On the Road to 50 States road trip campaign, Maaike Everts and Reese Fraser of Evonik Parenteral Drug Delivery Solutions talk to Nigel about new therapies that are being developed through cell and gene therapy innovation and how Evonik has been on the forefront of the mRNA LNP space for quite some time.

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.

Evonik Industries

Evonik Industries supports patient-friendly health care with a number of product developments for the pharmaceutical industry and medical technology. The company is contracted by pharmaceutical companies to produce active ingredient precursors, active ingredients and highly potent active ingredients under strict quality specifications. Evonik also produces pharmaceutical amino acids that are used in life-saving infusions and in the production of active pharmaceutical ingredients. Additionally, the company offers technology appropriate for the body, such as tablet coatings that release active ingredients at a precisely specified time to optimize efficacy. Evonik Industries is headquartered in Essen, Germany and owned by RAG Foundation.

Q: